medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2011, Number 5

<< Back Next >>

Salud Mental 2011; 34 (5)

Epidemiología y manejo integral de la discapacidad intelectual

Márquez-Caraveo ME, Zanabria-Salcedo M, Pérez-Barrón V, Aguirre-García E, Arciniega-Buenrostro L, Galván-García CS

Language: Spanish
References: 61
Page: 443-449
PDF size: 95.15 Kb.


ABSTRACT

Intellectual disability (ID) is a condition of limited intellectual and adaptive functioning that occurs before the age of 18 years. For varied reasons, ID is the most forgotten of public health programs.
Exact prevalence is unknown, due to the absence of epidemiological research in children and adolescents, which is essential to know the needs of this population.
Detection involves identifying children at risk for any type of atypical development with emphasis on language probes and dysmorphic searching, optimally combined with developmental screening tools with proven psychometric properties; training psychologists and health providers such as general practitioners or pediatricians in the first level of attention is needed. The goal of second-level intervention is to diagnose ID with an emphasis on accurate measurement of intellectural coeficcient (IC) and adaptive level, including expanded genetic medical evaluation and assessment of the personal, familiar, and community resources of children with suspected ID. We also recommend the use of existing classifications, employing the World Health Organization (WHO) International Classification of Functioning, Disability and Health, to identify individual and environmental barriers and facilitators and the application of appropriate tests.
The overall treatment includes specific medical, psychological and educative & social interventions. Medical intervention also includes pharmacological treatments, especially psychotropic medication, including risperidone, methylphenidate and melatonin. Developing evidence for the use of this medication is provided for challenging behaviors such as aggression, hyperactivity, sleep problems and depression. Psychological help includes psychoeducation and techniques evidence based, such as those derived from applied behavior analysis and cognitive behavior. Its chronic use is discouraged and medication is recommended to be combined with proper behavior management. Early and appropriate education for ID is lacking; which also requires improving access to health services, limiting social exclusion. Enhancing advocacy and promoting the human rights for this population is also needed.


REFERENCES

  1. World Health Organization (WHO). Atlas: Global resources for persons with intellectual disabilities 2007. Geneva; 2007.

  2. Organización Mundial de la Salud (OMS). CIE 10. Trastornos mentales y del comportamiento: descripciones clínicas y pautas para el diagnóstico. Madrid: Meditor; 1992.

  3. López-Ibor JJ, Valdés MM. DSM-IV-TR. Manual diagnóstico y estadístico de los trastornos mentales. Texto revisado. Barcelona: Masson; 2002.

  4. World Health Organization (WHO). Mental health policy and service guidance Package: Child and adolescent mental health policies and plans. Geneva; 2005.

  5. Frey GC, Temple VA. Health promotion for Latin Americans with intellectual disabilities. Salud Pública Méx 2008;50:167-177

  6. Salvador-Carulla L, Rodríguez-Blázquez C, Martorell A. Intellectual disability:an approach from the health sciences perspective. Salud Pública Méx 2008;50(2):142-150.

  7. Organización Panamericana de la Salud PAHO. De datos básicos a índices compuestos: una revisión del análisis de mortalidad. Bol Epidem 2002;23:1-6.

  8. World Health Organization. The global burden of disease 2004 update. Consultado en http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf el 29 junio de 2011.

  9. Katz GG, Rangel G, Lazcano E. Discapacidad intelectual. México: Instituto Nacional de Salud Pública; 2008.

  10. Instituto Nacional de Estadística, Geografía e Informática. Síntesis metodológica y conceptual del Censo de Población y Vivienda 2010. México; 2011.

  11. Katz GG, Márquez CME, Lazcano PE. Perspectives of intellectual disability in Mexico: epidemiology, policy, and services for children and adults. Curr Opin Psychiatry 2010;23(5):432–435.

  12. Katz G, Lazcano-Ponce E. Intellectual disability: definition, etiological factors, classification, diagnosis, treatment and prognosis. Salud Pública Méx 2008;50(2):132-141.

  13. Márquez-Caraveo ME, Zanabria-Salcedo M, Díaz-Pichardo JA, Arciniega-Buenrostro L et al. Guía de retraso mental. En: Ulloa R, Fernández C, Gómez H, Ramírez J, Reséndiz J (eds). Guías clínicas. Hospital Psiquiátrico Infantil «Dr. Juan N. Navarro». México D.F.: 2010; pp. 239-265. Consultado en http://www.sap.salud.gob.mx/downloads/pdf/nav_guias9.pdf&embedded=true&chrome=true el 20 mayo 2011.

  14. Benjet C, Borges G, Medina-Mora ME, Zambrano J et al. Youth mental health in a populous city of the developing world: results from the Mexican Adolescent Mental Health Survey. J Child Psychol Psychiatry 2009;50:386-395.

  15. Medina M, Borges G, Lara C, Benjet C et al. Prevalencia de trastornos mentales y uso de servicios: Resultados de la Encuesta Nacional de Epidemiologia Psiquiátrica en México. Salud Mental 2003;4:1-15.

  16. Caraveo AJ, Colmenares BE, Martínez VN. Síntomas, percepción y demanda de atención en salud mental en niños y adolescentes de la Ciudad de México. Salud Pública México 2002;44:492-498.

  17. Glascoe FP. Parents’ concerns about children’s development: prescreening technique or screening test? Pediatrics 2006;4:522-528.

  18. Balogh R, Ouellette-Kuntz H, Bourne L, Lunsky Y et al. Organización de los servicios sanitarios para pacientes con una discapacidad intelectual (revisión Cochrane traducida); 2008. Consultado en http://www.update-software.com. el 15 julio de 2011.

  19. Filipek PA, Accardo PJ, Baranek GT, Cook EH et al. The screening and diagnosis of autistic spectrum disorders. J Autism Dev Disord 1999;29: 439-484.

  20. Bayley N. Bayley Scales of Infant and Toddler Development. San Antonio, TX: Tercera edición; Harcourt Assessment; 2006.

  21. Glen P, Aylward GP, Verhuls SJ. Predictive utility of the Bayley Infant Neurodevelopmental Screener (BINS) risk status classifications: clinical interpretation and application. Dev Med Child Neurol 2000;42:25–31.

  22. Glascoe FP. A validation study and the psychometric properties of the BRIGANCE R Screens. North Billerica: Curriculum Associate; 1996.

  23. Glascoe FP. Collaborating with parents: using parents’ evaluation of developmental status to detect and address developmental and behavioural problems. Nashville: Ellsworth & Vandermeer; 1998.

  24. Bricker D, Squires J. Ages and Stages Questionnaires. Baltimore: Paul H. Brookes; 1994.

  25. Ireton H. Child development inventories. Minneapolis: Behavior Science Systems; 1992.

  26. Ireton H, Glascoe FP. Assessing children´s development using parents reports. The Child Development Inventory. Clin Pediatr (Phila) 1995;34: 248-255.

  27. Sánchez C, Mandujano M, Martínez I, Muñoz L et al. Los procedimientos de tamizaje para la evaluación y el seguimiento del desarrollo infantil. Rev Cienc Clín 2004;5(1):11-20.

  28. State MW, King BH, Dykens E. Mental retardation: A review of the past 10 years. Parte II. J Am Acad Child Adolesc Psychiatry 1997;36(12):1656-1663.

  29. Wechsler D. Escala Wechsler de inteligencia para niños-IV. México: El Manual Moderno; 2007.

  30. Sparrow S, Cicchetti D, Balla D. Vineland-II. Vineland adaptive behavior scales. Survey forms manual. Minneapolis: NCS Pearson Inc; 2005.

  31. Moeschler JB, Shevell M. the committee on genetics. Clinical genetic evaluation of the child mental retardation or developmental delays. Pediatrics 2006;117:2304-2315. Consultado en: http://pediatrics.aappublications.org/cgi/content/full/117/6/2304 el 6 agosto de 2009.

  32. Acevedo S. Seguimiento citogenético e hibridación in situ (FISH) en la enfermedad mínima residual. Medicina (Buenos Aires) 2000;60:87-90.

  33. Van Karnebeek MD, Scheper YF. Etiology of mental retardation in children referred to a tertiary care center: A prospective study. Am J Ment Retard 2005;110(4):253-256.

  34. Organización Mundial de la Salud. Clasificación internacional del funcionamiento de la discapacidad y de la salud: CIF. Madrid; 2001.

  35. Vega ME, Chávez R. Algoritmo clínico-biológico para el diagnóstico de los errores innatos del metabolismo en neonatos enfermos. Rev Mex Pediatr 1999;66:64-70.

  36. Sevin JA, Stephens BCh, Hamilton ML. Integrating behavioral and pharmacological interventions in treating clients with psychiatric disorders and mental retardation. Res Dev Disabil 2001;22:463–485.

  37. Hässler F, Reis O. Pharmacotherapy of disruptive behavior in mentally retarded subjects. Dev Disabil Res Rev 2010;16(3):265-272.

  38. Tsiouris JA. Pharmacotherapy for aggressive behaviours in persons with intellectual disabilities: treatment or mistreatment? J Intellect Disabil Res 2010;54(1):1-16.

  39. Baasland G, Engedal K. Use of psychotropic medication among individuals with mental retardation. Tidsskr Nor Laegeforen 2009;129(17): 1751-1753.

  40. Valdovinos MG, Schroeder SR, Kim G. Prevalence and correlates of psychotropic medication use among adults with Developmental Disabilities: 1970-2000. Int Rev Res Ment Ret 2003;26:175-220.

  41. Artigas PJ. Tratamiento farmacológico del retraso mental. Rev Neurol 2006;42(1):S109-S115.

  42. Stahl S. Essential psychopharmacology: The prescriber’s guide. New York: Cambridge University Press; 2007.

  43. Pearson D, Santos C, Casat Ch, Lane D et al. Treatment effects of methylphenidate on cognitive functioning in children with mental retardation and ADHD. J Am Acad Child Adolesc Psychiatry 2004;43:677-685.

  44. Fernández J, Fernández M, Calleja P, Muñoz J et al. Atomoxetine for attention déficit hyperactivity disorder in mental retardation. Pediatr Neurol 2010;43(5):341-347.

  45. Bramble D, Feehan C. Psychiatrists’ use of melatonin with children. Child Adolesc Ment Health 2005;10:145–149.

  46. Sajith SG, Clarke D. Melatonin and sleep disorders associated with intellectual disability: a clinical review. J Intellect Disabil Res 2007;51:2-13.

  47. Bramble D. Psychopharmacology in children with intellectual disability. Advances Psychiatric Treatment 2011;17:32–40.

  48. Thomson A, Maltezos S, Poliakosta E, Xenitidis K. Risperidona para el trastorno por hiperactividad y déficit de atención en pacientes con discapacidad intelectual. The Cochrane Library 2009. Consultado en: http://www.update-software.com/ el 10 julio de 2011.

  49. Ghosh S, Arulrajan AE, Baldwin D. Unlicensed applications of licensed psychotropic drugs in an intellectual disability clinical service: retrospective case-note study. J Intellect Disabil 2010:14:237-243.

  50. Gibson RW, D’Amico M, Jaffe L, Arbesman M. Occupational therapy interventions for recovery in the areas of community integration and normative life roles for adults with serious mental illness: a systematic review. Am J Occup Ther 2011;65:247-256.

  51. Van der Schuit M, Segers E, van Balkom H, Verhoeven L. Early language intervention for children with intellectual disabilities: a neurocognitive perspective. Res Dev Disabil 2011;32:705-712.

  52. Grey I, Hastings R. Evidence-based practices in intellectual disability and behaviour disorders. Curr Opin Psychiatry 2005;18:469-475.

  53. Taylor JL, Lindsay WR, Willner P. CBT for people with Intellectual Disabilities: Emerging Evidence, Cognitive and IQ Effects. Behav Cogn Psychother 2008;36:723–733.

  54. Willner P. Cognitive behaviour therapy for people with learning disabilities: focus on anger. Advances Mental Health Learning Disabilities 2007;1:14–21.

  55. Buntinx WHE, Schalock RL. Models of disability, quality of life, and individualized supports: implications for professional practice in intellectual disability. J Intellect Disabil Res 2010;4:283-294.

  56. King BH, State MW, Shah B, Davanzo P et al. Mental retardation: A review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry 1997;36:1656-1663.

  57. Organización Panamericana de la Salud. La salud en las Américas. Edición 2002. Washington D.C.: OPS; 2002.

  58. Secretaría de Educación Pública. Guía para facilitar la inclusión de alumnos y alumnas con discapacidad en escuelas que participan en el Programa Escuelas de Calidad, Modulo VI. México; 2010.

  59. Comisión de Expertos de Educación Especial. Nueva perspectiva y visión de la educación especial. Santiago, Chile: Ministerio de Educación (MINEDUC); 2004.

  60. Ministerio de Educación de Chile. Necesidades educativas especiales asociadas a retraso del desarrollo y discapacidad intelectual: Guía de apoyo técnico-pedagógico: Necesidades educativas especiales en el nivel de educación parvularia. Santiago de Chile; 2007.

  61. Fletcher T, Dejud C, Klingler C, López MI. The changing paradigm of special education in Mexico: Voices from the field. Bilingual Research J 2003;27(3):409-441.




2020     |     www.medigraphic.com